Novel Estrogen Receptor Modulators
J ournal of Medicinal Chemistry, 2002, Vol. 45, No. 25 5505
(13) Hewitt, S. C.; Couse, J . F.; Korach, K. S. Estrogen receptor
transcription and transactivation. Estrogen receptor knockout
mice: what their phenotypes reveal about mechanisms of
estrogen action. Breast Cancer Res. 2000, 2, 345-352.
(14) Couse, J . F.; Korach, K. S. Estrogen receptor null mice: what
have we learned and where will they lead us? Endocr. Rev. 1999,
20, 358-417.
(15) Dupont, S.; Krust, A.; Gansmuller, A.; Dierich, A.; Chambon,
P.; et al. Effect of single and compound knockouts of estrogen
receptors R (ERR) and â (ERâ) on mouse reproductive pheno-
types. Development 2000, 127, 4277-4291.
(16) Barkhem, T.; Carlsson, B.; Nilsson, Y.; Enmark, E.; Gustafsson,
J .-A.; et al. Differential response of estrogen receptor R and
estrogen receptor â to partial estrogen agonists/antagonists. Mol.
Pharmacol. 1998, 54, 105-112.
(17) Meyers, M. J .; Sun, J .; Carlson, K. E.; Katzenellenbogen, B. S.;
Katzenellenbogen, J . A. Estrogen Receptor Subtype-Selective
Ligands: Asymmetric Synthesis and Biological Evaluation of cis-
and trans-5,11-Dialkyl-5,6,11,12-tetrahydrochrysenes. J . Med.
Chem. 1999, 42, 2456-2468.
(33) Miller, C. P.; Collini, M. D.; Tran, B. D.; Harris, H. A.; Kharode,
Y. P.; et al. Design, Synthesis, and Preclinical Characterization
of Novel, Highly Selective Indole Estrogens. J . Med. Chem. 2001,
44, 1654-1657.
(34) Minutolo, F.; Bertini, S.; Papi, C.; Carlson, K. E.; Katzenellen-
bogen, J . A.; et al. Salicylaldoxime Moiety as a Phenolic “A-Ring”
Substitute in Estrogen Receptor Ligands. J . Med. Chem. 2001,
44, 4288-4291.
(35) Nishiguchi, G. A.; Rodriguez, A. L.; Katzenellenbogen, J . A.
Diaryl-dialkyl-substituted pyrazoles: regioselective synthesis
and binding affinity for the estrogen receptor. Bioorg. Med.
Chem. Lett. 2002, 12, 947-950.
(36) Sun, J .; Huang, Y. R.; Harrington, W. R.; Sheng, S.; Katzenel-
lenbogen, J . A.; et al. Antagonists selective for estrogen receptor
R. Endocrinology 2002, 143, 941-947.
(37) Anstead, G. M.; Carlson, K. E.; Katzenellenbogen, J . A. The
estradiol pharmacophore: ligand structure-estrogen receptor
binding affinity relationships and a model for the receptor
binding site. Steroids 1997, 62, 268-303.
(18) Stauffer, S. R.; Coletta, C. J .; Tedesco, R.; Nishiguchi, G.;
Carlson, K.; et al. Pyrazole Ligands: Structure-Affinity/Activity
Relationships and Estrogen Receptor-R Selective Agonists. J .
Med. Chem., 2000, 43, 4934-4947.
(19) Stauffer, S. R.; Sun, J .; Katzenellenbogen, B. S.; Katzenellen-
bogen, J . A. Acyclic amides as estrogen receptor ligands: Syn-
thesis, binding, activity and receptor interaction. Bioorg. Med.
Chem. 2000, 8, 1293-1316.
(20) Sun, J .; Meyers, M. J .; Fink, B. E.; Rajendran, R.; Katzenellen-
bogen, J . A.; et al. Novel ligands that function as selective
estrogens or antiestrogens for estrogen receptor-R or estrogen
receptor-â. Endocrinology 1999, 140, 800-804.
(21) Schopfer, U.; Schoeffter, P.; Bischoff, S. F.; Nozulak, J .; Feuer-
bach, D.; et al. Toward Selective ERâ Agonists for Central
Nervous System Disorders: Synthesis and Characterization of
Aryl Benzthiophenes. J . Med. Chem. 2002, 45, 1399-1401.
(22) Meyers, M. J .; Sun, J .; Carlson, K. E.; Marriner, G. A.; Katzenel-
lenbogen, B. S.; et al. Estrogen Receptor-â Potency-Selective
Ligands: Structure-Activity Relationship Studies of Diarylpro-
pionitriles and Their Acetylene and Polar Analogues. J . Med.
Chem. 2001, 44, 4230-4251.
(23) Masquelin, T.; Meunier, N.; Gerber, F.; Rosse, G. Solution- and
solid-phase synthesis of combinatorial libraries of trisubstituted
1,3,5-triazines. Heterocycles 1998, 48, 2489-2505.
(24) Scharn, D.; Wenschuh, H.; Reineke, U.; Schneider-Mergener, J .;
Germeroth, L. Spatially Addressed Synthesis of Amino- and
Amino-Oxy-Substituted 1,3,5-Triazine Arrays on Polymeric
Membranes. J . Comb. Chem. 2000, 2, 361-369.
(25) Scharn, D.; Germeroth, L.; Schneider-Mergener, J .; Wenschuh,
H. Sequential Nucleophilic Substitution on Halogenated Triaz-
ines, Pyrimidines, and Purines: A Novel Approach to Cyclic
Peptidomimetics. J . Org. Chem. 2001, 66, 507-513.
(26) Nichols, J . S.; Parks, D. J .; Consler, T. G.; Blanchard, S. G.
Development of a scintillation proximity assay for peroxisome
proliferator-activated receptor γ ligand binding domain. Anal.
Biochem. 1998, 257, 112-119.
(27) Mortensen, D. S.; Rodriguez, A. L.; Sun, J .; Katzenellenbogen,
B. S.; Katzenellenbogen, J . A. Furans with basic side chains:
synthesis and biological evaluation of a novel series of antago-
nists with selectivity for the estrogen receptor alpha. Bioorg.
Med. Chem. Lett. 2001, 11, 2521-2524.
(28) Henke, B. R.; Drewry, D. H.; J ones, S. A.; Stewart, E. L.; Weaver,
S. L.; et al. 2-Amino-4,6-diarylpyridines as novel ligands for the
estrogen receptor. Bioorg. Med. Chem. Lett. 2001, 11, 1939-
1942.
(29) Lesuisse, D.; Albert, E.; Bouchoux, F.; Cerede, E.; Lefrancois, J .
M.; et al. Biphenyls as surrogates of the steroidal backbone. Part
1: synthesis and estrogen receptor affinity of an original series
of polysubstituted biphenyls. Bioorg. Med. Chem. Lett. 2001, 11,
1709-1712.
(30) Endo, Y.; Iijima, T.; Yamakoshi, Y.; Fukasawa, H.; Miyaura, C.;
et al. Potent estrogen agonists based on carborane as a hydro-
phobic skeletal structure: a new medicinal application of boron
clusters. Chem. Biol. 2001, 8, 341-355.
(31) Tedesco, R.; Youngman, M. K.; Wilson, S. R.; Katzenellenbogen,
J . A. Synthesis and evaluation of hexahydrochrysene and
tetrahydrobenzofluorene ligands for the estrogen receptor. Bioorg.
Med. Chem. Lett. 2001, 11, 1281-1284.
(32) Stauffer, S. R.; Huang, Y.; Coletta, C. J .; Tedesco, R.; Katzenel-
lenbogen, J . A. Estrogen pyrazoles: defining the pyrazole core
structure and the orientation of substituents in the ligand
binding pocket of the estrogen receptor. Bioorg. Med. Chem.
2001, 11, 141-150.
(38) Brzozowski, A. M.; Pike, A. C. W.; Dauter, Z.; Hubbard, R. E.;
Bonn, T.; et al. Molecular basis of agonism and antagonism in
the estrogen receptor. Nature 1997, 389, 753-758.
(39) Wurtz, J .-M.; Egner, U.; Heinrich, N.; Moras, D.; Mueller-
Fahrnow, A. Three-Dimensional Models of Estrogen Receptor
Ligand Binding Domain Complexes, Based on Related Crystal
Structures and Mutational and Structure-Activity Relationship
Data. J . Med. Chem. 1998, 41, 1803-1814.
(40) Pike, A. C. W.; Brzozowski, A. M.; Hubbard, R. E.; Bonn, T.;
Thorsell, A.-G.; et al. Structure of the ligand-binding domain of
oestrogen receptor beta in the presence of a partial agonist and
a full antagonist. EMBO J . 1999, 18, 4608-4618.
(41) Egner, U.; Heinrich, N.; Ruff, M.; Gangloff, M.; Mueller-Fahrnow,
A.; et al. Different ligands-different receptor conformations:
modeling of the hERR LBD in complex with agonists and
antagonists. Med. Res. Rev. 2001, 21, 523-539.
(42) Tanenbaum, D. M.; Wang, Y.; Williams, S. P.; Sigler, P. B.
Crystallographic comparison of the estrogen and progesterone
receptor’s ligand binding domains. Proc. Natl. Acad. Sci. U.S.A.
1998, 95, 5998-6003.
(43) Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P.
J .; et al. The structural basis of estrogen receptor/coactivator
recognition and the antagonism of this interaction by tamoxifen.
Cell 1998, 95, 927-937.
(44) Matthews, J .; Celius, T.; Halgren, R.; Zacharewski, T. Dif-
ferential estrogen receptor binding of estrogenic substances: a
species comparison. J . Steroid Biochem. Mol. Biol. 2000, 74,
223-234.
(45) Sanderson, J . T.; Seinen, W.; Giesy, J . P.; Van den Berg, M.
2-Chloro-s-triazine herbicides induce aromatase (CYP19) activity
in H295R human adrenocortical carcinoma cells: a novel mech-
anism for estrogenicity? Toxicol. Sci. 2000, 54, 121-127.
(46) Sanderson, J . T.; Letcher, R. J .; Heneweer, M.; Giesy, J . P.; Van
den Berg, M. Effects of chloro-s-triazine herbicides and metabo-
lites on aromatase activity in various human cell lines and on
vitellogenin production in male carp hepatocytes. Environ.
Health Perspect. 2001, 109, 1027-1031.
(47) Klinge, C. M. Estrogen receptor interaction with estrogen
response elements. Nucleic Acids Res. 2001, 29, 2905-2919.
(48) Foster, A. B.; J arman, M.; Leung, O. T.; McCague, R.; Leclercq,
G.; et al. Hydroxy derivatives of tamoxifen. J . Med. Chem. 1985,
28, 1491-1497.
(49) Grese, T. A.; Cho, S.; Finley, D. R.; Godfrey, A. G.; J ones, C. D.;
et al. Structure-Activity Relationships of Selective Estrogen
Receptor Modulators: Modifications to the 2-Arylbenzothiophene
Core of Raloxifene. J . Med. Chem. 1997, 40, 146-167.
(50) Lambert, M. H. Docking conformationally flexible molecules into
protein binding sites. In Practical Application of Computer-Aided
Drug Design; Charifson, P. S., Ed.; Marcel Dekker: New York,
1997; Chapter 8, pp 243-303.
(51) Insight II is available from Accelrys, Inc., San Diego, CA 92121.
(52) Pike, A. C. W.; Brzozowski, A. M.; Walton, J .; Hubbard, R. E.;
Thorsell, A.-G.; et al. Structural insights into the mode of action
of a pure antiestrogen. Structure 2001, 9, 145-153.
(53) Shiau, A. K.; Barstad, D.; Radek, J . T.; Meyers, M. J .; Nettles,
K. W.; et al. Structural characterization of a subtype-selective
ligand reveals a novel mode of estrogen receptor antagonism.
Nat. Struct. Biol. 2002, 9, 359-364.
J M020291H